Posterior cingulate γ-aminobutyric acid and glutamate/glutamine are reduced in amnestic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype

The biomarker potential of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) for the in vivo characterization of preclinical stages in Alzheimer's disease has not yet been explored. We measured GABA, glutamate + glutamine (Glx), and N-acetyl-aspartate (NAA) levels by single-voxel MEGA-PRESS magnetic resonance spectroscopy in the posterior cingulate cortex of 21 elderly subjects and 15 patients with amnestic mild cognitive impairment. Participants underwent Pittsburgh Compound B positron emission tomography, apolipoprotein E (APOE) genotyping, and neuropsychological examination. GABA, Glx, and NAA levels were significantly lower in patients. NAA was lower in Pittsburgh Compound B-positive subjects and APOE ε4 allele carriers. GABA, Glx, and NAA levels were positively correlated to CERAD word learning scores. Reductions in GABA, Glx, and NAA levels may serve as metabolic biomarkers for cognitive impairment in amnestic mild cognitive impairment. Because GABA and Glx do not seem to reflect amyloid β deposition or APOE genotype, they are less likely biomarker candidates for preclinical Alzheimer's disease.

[1]  Daniel Rueckert,et al.  Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest , 2008, NeuroImage.

[2]  N. Fayed,et al.  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.

[3]  Peter B Barker,et al.  Spatial effects in the detection of γ‐aminobutyric acid: Improved sensitivity at high fields using inner volume saturation , 2007, Magnetic resonance in medicine.

[4]  P. Barker,et al.  MR spectroscopy and spectroscopic imaging of the brain. , 2011, Methods in molecular biology.

[5]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[6]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  C. Rivera,et al.  Neurturin Evokes MAPK-Dependent Upregulation of Egr4 and KCC2 in Developing Neurons , 2011, Neural plasticity.

[8]  Ileana Hancu,et al.  Optimized glutamate detection at 3T , 2009, Journal of magnetic resonance imaging : JMRI.

[9]  N Butters,et al.  Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. , 1992, Archives of neurology.

[10]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[11]  Nikolaus Weiskopf,et al.  A comparison between voxel-based cortical thickness and voxel-based morphometry in normal aging , 2009, NeuroImage.

[12]  Peter Boesiger,et al.  ProFit revisited , 2014, Magnetic resonance in medicine.

[13]  Derek K. Jones,et al.  Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans , 2009, Proceedings of the National Academy of Sciences.

[14]  N. Herrmann,et al.  GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[15]  R. Edden,et al.  In vivo magnetic resonance spectroscopy of GABA: a methodological review. , 2012, Progress in nuclear magnetic resonance spectroscopy.

[16]  S. Borson,et al.  Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. , 2013, JAMA neurology.

[17]  P. Boesiger,et al.  GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI , 2007, Nature Neuroscience.

[18]  M. Richardson,et al.  Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. , 2003, Brain : a journal of neurology.

[19]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.

[20]  J. Herz,et al.  ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling , 2010, Proceedings of the National Academy of Sciences.

[21]  Arvind Caprihan,et al.  Use of tissue water as a concentration reference for proton spectroscopic imaging , 2006, Magnetic resonance in medicine.

[22]  D. Lewis,et al.  GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia , 2011, Neural plasticity.

[23]  S. Dumanis,et al.  APOE genotype affects the pre‐synaptic compartment of glutamatergic nerve terminals , 2013, Journal of neurochemistry.

[24]  Peter Boesiger,et al.  SELOVS: Brain MRSI localization based on highly selective T1‐ and B1‐insensitive outer‐volume suppression at 3T , 2008, Magnetic resonance in medicine.

[25]  C. Jack,et al.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. , 2008, Radiology.

[26]  C. Rae.  A Guide to the Metabolic Pathways and Function of Metabolites Observed in Human Brain 1H Magnetic Resonance Spectra , 2013, Neurochemical Research.

[27]  David A Wolk,et al.  Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer’s disease , 2010, Proceedings of the National Academy of Sciences.

[28]  C. John Evans,et al.  Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA , 2014, NeuroImage.

[29]  Huiquan Wang,et al.  Edited magnetic resonance spectroscopy detects an age-related decline in brain GABA levels , 2013, NeuroImage.

[30]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[31]  Keith A. Johnson,et al.  Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia , 2009, Neuron.

[32]  Jonathan Graff-Radford,et al.  Magnetic resonance spectroscopy in Alzheimer’s disease , 2013, Neuropsychiatric disease and treatment.

[33]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[34]  C. Jack,et al.  MRI and MRS predictors of mild cognitive impairment in a population-based sample , 2013, Neurology.

[35]  C. Jack,et al.  Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults , 2011, Neurology.

[36]  Peter Boesiger,et al.  Electrocardiogram‐triggered, higher order, projection‐based B0 shimming allows for fast and reproducible shim convergence in spinal cord 1H MRS , 2013, NMR in biomedicine.

[37]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[38]  R. Gruetter,et al.  In vivo 1H NMR spectroscopy of rat brain at 1 ms echo time , 1999, Magnetic resonance in medicine.

[39]  N. Fayed,et al.  Brain Glutamate Levels Are Decreased in Alzheimer’s Disease , 2011, American journal of Alzheimer's disease and other dementias.

[40]  K. Kantarci.  Proton MRS in mild cognitive impairment , 2013, Journal of magnetic resonance imaging : JMRI.

[41]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[42]  C. Jack,et al.  Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.

[43]  R. Bartha,et al.  Reduced hippocampal glutamate in Alzheimer disease , 2011, Neurobiology of Aging.

[44]  A. Lawrence,et al.  Dorsolateral Prefrontal-Aminobutyric Acid in Men Predicts Individual Differences in Rash Impulsivity , 2011 .

[45]  A. Bompas,et al.  More GABA, less distraction: a neurochemical predictor of motor decision speed , 2010, Nature Neuroscience.

[46]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[47]  P. Antuono,et al.  Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with 1H-MRS at 0.5 T , 2001, Neurology.

[48]  Theodoros N. Arvanitis,et al.  A constrained least‐squares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data , 2011, Magnetic resonance in medicine.

[49]  Andrew J. Saykin,et al.  Increased brain activation during working memory in cognitively intact adults with the APOE ε4 allele , 2006 .

[50]  David J. Nutt,et al.  GABA system dysfunction in autism and related disorders: From synapse to symptoms , 2012, Neuroscience & Biobehavioral Reviews.

[51]  Daniel Brandeis,et al.  Frontal GABA Levels Change during Working Memory , 2012, PloS one.

[52]  Rolf Gruetter,et al.  The neurochemical profile quantified by in vivo 1H NMR spectroscopy , 2012, NeuroImage.

[53]  D. Head,et al.  Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly , 2010, Biological Psychiatry.

[54]  Yadong Huang,et al.  Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice , 2010, The Journal of Neuroscience.

[55]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[56]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[57]  Miia Kivipelto,et al.  Introduction: Mild cognitive impairment: beyond controversies, towards a consensus , 2004 .

[58]  F. Castellanos,et al.  An 1H-MRS framework predicts the onset of Alzheimer's disease symptoms in PSEN1 mutation carriers , 2014, Alzheimer's & Dementia.

[59]  Sander Martens,et al.  Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis , 2013, Neuroscience & Biobehavioral Reviews.

[60]  Krish D. Singh,et al.  Orientation Discrimination Performance Is Predicted by GABA Concentration and Gamma Oscillation Frequency in Human Primary Visual Cortex , 2009, The Journal of Neuroscience.